Kathleen B. Fedan
National Institute for Occupational Safety and Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kathleen B. Fedan.
Journal of Occupational and Environmental Medicine | 2006
Richard Kanwal; Greg Kullman; Chris Piacitelli; Randy Boylstein; Nancy Sahakian; Stephen B. Martin; Kathleen B. Fedan; Kathleen Kreiss
Objective: After investigating fixed airways obstruction in butter flavoring-exposed workers at a microwave popcorn plant, we sought to further characterize lung disease risk from airborne butter-flavoring chemicals. Methods: We analyzed data from medical and environmental surveys at six microwave popcorn plants (including the index plant). Results: Respiratory symptom and airways obstruction prevalences were higher in oil and flavorings mixers with longer work histories and in packaging-area workers near nonisolated tanks of oil and flavorings. Workers were affected at five plants, one with mixing-area exposure to diacetyl (a butter-flavoring chemical with known respiratory toxicity potential) as low as 0.02 ppm. Conclusions: Microwave popcorn workers at many plants are at risk for flavoring-related lung disease. Peak exposures may be hazardous even when ventilation maintains low average exposures. Respiratory protection and engineering controls are necessary to protect workers.
Public Health Reports | 2011
Richard Kanwal; Greg Kullman; Kathleen B. Fedan; Kathleen Kreiss
Objectives. After an outbreak of severe lung disease among workers exposed to butter-flavoring chemicals at a microwave popcorn plant, we determined whether or not lung disease risk declined after implementation of exposure controls. Methods. National Institute for Occupational Safety and Health staff performed eight serial cross-sectional medical and industrial hygiene surveys at the plant from November 2000 through August 2003. Medical surveys included standardized questionnaires and spirometry testing. Industrial hygiene surveys measured levels of production-related air contaminants, including butter-flavoring chemicals such as diacetyl. All diacetyl concentrations above detectable limits were corrected for the effects of absolute humidity and days to sample extraction. Results. Ventilation and isolation of the production process resulted in one to three orders of magnitude reductions in diacetyl air concentrations in different areas of the plant. Workers with past high exposures had stable chest symptoms over time; nasal, eye, and skin irritation symptoms declined. New workers had lower symptom prevalences and higher lung function than workers with past high exposures, and they did not worsen over time. In workers who had at least three spirometry tests, those with past high exposures were more likely to experience rapid declines in lung function than new workers. Conclusions. Implemented controls lowered exposures to butter-flavoring chemicals and decreased lung disease risk for much of the plant workforce. Some workers with continuing potential for intermittent, short-term peak and measurable time-weighted exposures remain at risk and should use respiratory protection and have regularly scheduled spirometry to detect rapid lung function declines that may be work-related. Close follow-up of such workers is likely to yield additional information on risks due to peak and time-weighted exposure levels.
American Journal of Industrial Medicine | 2012
Kathleen Kreiss; Kathleen B. Fedan; Muazzam Nasrullah; Thomas J. Kim; Barbara L. Materna; Janice C. Prudhomme; Paul L. Enright
BACKGROUND The California Department of Public Health received serial spirometry data for flavoring manufacturing workers at 20 companies at risk of bronchiolitis obliterans. METHODS We graded spirometry quality; identified individual workers with excessive decline in forced expiratory volume in 1 s (FEV(1)) using relative longitudinal limits of decline based on 4% average within-person variability; and analyzed declines by occupational risk factors. RESULTS The quality of 1,696 spirometry tests from 724 workers varied by 17 providers, with poorer quality from commercial providers. Of 416 workers with at least two tests, 40 (9.6%) had abnormal FEV(1) decline. Of 289 workers with high quality spirometry, 21 (7.3%) had abnormal decline. Only one of the 21 had airways obstruction. Abnormal FEV(1) decline rates (per person-month) were greater among workers at companies using ≥800 lbs/year diacetyl than at companies using lesser amounts. Abnormal FEV(1) decline rates were greater at companies previously having four-person clusters of spirometric obstruction than at companies with no or only one worker with obstruction. CONCLUSIONS Spirometric surveillance of flavoring workers can identify individual workers with an abnormal FEV(1) decline for preventive intervention, even when the FEV(1) itself remains within the normal range. Good quality spirometry and classification of abnormal with relative longitudinal limit of decline minimize misclassification of possible work-related health effects.
Morbidity and Mortality Weekly Report | 2016
Brie Hawley; Megan L. Casey; Jean M. Cox-Ganser; Nicole Edwards; Kathleen B. Fedan; Kristin J. Cummings
In March 2014, a new disinfection product, consisting of hydrogen peroxide, peroxyacetic acid, and acetic acid, was introduced at a Pennsylvania hospital to aid in the control of health care-associated infections. The product is an Environmental Protection Agency-registered non-bleach sporicide advertised as a one-step cleaner, disinfectant, and deodorizer. According to the manufacturers safety data sheet, the product requires no personal protective equipment when it is diluted with water by an automated dispenser before use. On January 30, 2015, CDCs National Institute for Occupational Health (NIOSH) received a confidential employee request to conduct a health hazard evaluation at the hospital. The request cited concerns about exposure of hospital environmental services staff members to the product and reported symptoms among persons who had used the product that included eye and nasal problems, asthma-like symptoms, shortness of breath, skin problems, wheeze, chest tightness, and cough.
The New England Journal of Medicine | 2002
Kathleen Kreiss; Ahmed Gomaa; Greg Kullman; Kathleen B. Fedan; Eduardo J. Simoes; Paul L. Enright
American Journal of Industrial Medicine | 2010
Thomas J. Kim; Barbara L. Materna; Janice C. Prudhomme; Kathleen B. Fedan; Paul L. Enright; Nancy Sahakian; Gayle C. Windham; Kathleen Kreiss
PLOS ONE | 2013
Cara N. Halldin; Eva Suarthana; Kathleen B. Fedan; Yi-Chun Lo; George Turabelidze; Kathleen Kreiss
Journal of The American Society of Hypertension | 2017
Megan L. Casey; Kathleen B. Fedan; Nicole Edwards; David J. Blackley; Cara N. Halldin; Anita L. Wolfe; Anthony Scott Laney
Archive | 2016
Lauralynn Taylor McKernan; R. Todd Niemeier; Kathleen Kreiss; F Hubbs Ann; Robert M. Park; David A. Dankovic; Kevin H. Dunn; Jay A. Parker; Kathleen B. Fedan; Robert P. Streicher; Jeffery S. Fedan; Alberto Garcia; Christine Whittaker; Stephen J. Gilbert; Fariba Nourian; Ellen Galloway; Randall J. Smith; Thomas J. Lentz; Deborah V. L. Hirst; Jennifer L. Topmiller; Brian Curwin
american thoracic society international conference | 2010
Kathleen Kreiss; Thomas J. Kim; Barbara J. Materna; Janice C. Prudhomme; Kathleen B. Fedan; Nancy Sahakian; Gayle C. Windham